Bluebird Bio Announces More Good News for LentiGlobin Gene Therapy – Exciting Results in Sickle Cell Disease

Bluebird Bio Announces More Good News for LentiGlobin Gene Therapy – Exciting Results in Sickle Cell Disease

Source: 
CP Wire
snippet: 
  • Early results in one group exceed initial therapeutic target
  • Patients (small number in Ph I currently) appear to remain stable for up to two years
  • LentiGlobin is being studied in both sickle cell disease and β-thalassemia
  • LentiGlobin granted orphan drug status in both sickle cell disease and β-thalassemia